News about Global Pharma

BioLineRx Gets USPTO Allowance of New Composition of Matter Patent on Motixafortide

The patent strengthens BioLineRx's robust intellectual property (IP) estate and extends its patent protection on motixafortide in the US through December 2041.

Global Pharma | 18/10/2024 | By Aishwarya |  475

Factor Bioscience Signs Exclusive License Deal with Eterna Therapeutics

The agreement positions both companies with the potential to accelerate the development of advanced cell therapies in the oncology, rare disease, and autoimmune fields.

Global Pharma | 18/10/2024 | By Aishwarya |  608

Cellular Origins, Fresenius Kabi to Scale Up Automation of Cell and Gene Therapy Manufacturing

The agreement is designed with the goal of digitally and physically integrating Fresenius Kabi’s suite of cell therapy processing technologies within Cellular Origins’ CGT robotic manufacturing platform Constellation.

Global Pharma | 17/10/2024 | By Aishwarya |  604

VGXI Picks Cryoport to Support its Supply Chain Solutions to Boost Next-Gen Therapies

VGXI is a contract developer and manufacturer specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines and RNA medicines, and ADC applications.

Global Pharma | 16/10/2024 | By Aishwarya |  448

OneSource Secures Equity Commitments of USD 95 Million for Fundraising

The strong interest from leading investors reflects growing confidence in our capabilities and the immense potential of the CDMO sector emerging out of India.

Global Pharma | 16/10/2024 | By Aishwarya |  695

Lupin Introduces First Generic Version of Pred Forte in US

Being the first generic to be approved and launched, the company is entitled to 180-day competitive generic therapy (CGT) exclusivity.

Global Pharma | 16/10/2024 | By Aishwarya |  504

Lundbeck to Acquire Longboard Pharmaceuticals to Expand its Neuroscience Pipeline

Under the terms of the agreement, Lundbeck will commence a tender offer for all outstanding shares of Longboard common stock, whereby Longboard shareholders will be offered a payment of USD 60.00 per share in cash.

Global Pharma | 15/10/2024 | By Aishwarya |  760

RedHill Biopharma Bags Funding Through BARDA to Advance Opaganib for Ebola Treatment

Under this cost-sharing contract, BARDA will provide partial funding for the company to further advance opaganib to mitigate infection and contain EBOV outbreaks.

Global Pharma | 15/10/2024 | By Aishwarya |  589

Akeso Receives USD 250 Million to Boost Global Expansion of its Drug Pipeline

Seventy percent of the financing will accelerate the global clinical development of innovative drugs developed internally by Akeso, with a primary focus on its core products in both China and international markets.

Global Pharma | 14/10/2024 | By Aishwarya |  709

NRA Meets WHO International Standards for Vaccine Regulations

WHO has established global standards and benchmarks for assurance of vaccine quality through the development of tools and guidelines, benchmarking of the NRA and prequalification programme of vaccines.

Global Pharma | 14/10/2024 | By Aishwarya |  733